BR0116672A - Pharmaceutically acceptable salt of a compound, compound, pharmaceutical composition, use of a pharmaceutically acceptable salt, and process for preparing a compound. - Google Patents
Pharmaceutically acceptable salt of a compound, compound, pharmaceutical composition, use of a pharmaceutically acceptable salt, and process for preparing a compound.Info
- Publication number
- BR0116672A BR0116672A BR0116672-7A BR0116672A BR0116672A BR 0116672 A BR0116672 A BR 0116672A BR 0116672 A BR0116672 A BR 0116672A BR 0116672 A BR0116672 A BR 0116672A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- formula
- preparing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
"SAL FARMACEUTICAMENTE ACEITáVEL DE UM COMPOSTO, COMPOSTO, COMPOSIçãO FARMACêUTICA, USO DE UM SAL FARMACEUTICAMENTE ACEITáVEL, E, PROCESSO PARA PREPARAR UM COMPOSTO". A presente invenção proporciona novos sais farmaceuticamente aceitáveis de compostos de Fórmula (I) e de Fórmula (Ia), bem como métodos para usar os sais farmaceuticamente aceitáveis, e também proporciona processos para preparar compostos de Fórmula (I) e de Fórmula (Ia), ou seus sais farmaceuticamente aceitáveis. Os compostos de Fórmula (I) e de Fórmula (Ia) são úteis para o tratamento de distúrbios neurológicos, especialmente de enxaqueca."Pharmaceutically acceptable salt of a compound, compound, pharmaceutical composition, use of a pharmaceutically acceptable salt, and process for preparing a compound". The present invention provides novel pharmaceutically acceptable salts of compounds of Formula (I) and Formula (Ia), as well as methods for using pharmaceutically acceptable salts, and also provides processes for preparing compounds of Formula (I) and Formula (Ia). or pharmaceutically acceptable salts thereof. The compounds of Formula (I) and Formula (Ia) are useful for the treatment of neurological disorders, especially migraine.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26001401P | 2001-01-05 | 2001-01-05 | |
| PCT/US2001/044715 WO2002053561A1 (en) | 2001-01-05 | 2001-12-20 | Excitatory amino acid receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0116672A true BR0116672A (en) | 2003-09-23 |
Family
ID=22987455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0116672-7A BR0116672A (en) | 2001-01-05 | 2001-12-20 | Pharmaceutically acceptable salt of a compound, compound, pharmaceutical composition, use of a pharmaceutically acceptable salt, and process for preparing a compound. |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP1351955A1 (en) |
| JP (1) | JP2004520335A (en) |
| KR (1) | KR20030066797A (en) |
| CN (1) | CN1484642A (en) |
| AR (1) | AR035679A1 (en) |
| BR (1) | BR0116672A (en) |
| CA (1) | CA2431545A1 (en) |
| CZ (1) | CZ20031856A3 (en) |
| DZ (1) | DZ3460A1 (en) |
| EA (1) | EA200300770A1 (en) |
| EC (1) | ECSP034682A (en) |
| HR (1) | HRP20030544A2 (en) |
| HU (1) | HUP0302528A2 (en) |
| IL (1) | IL156138A0 (en) |
| MX (1) | MXPA03005981A (en) |
| NO (1) | NO20032973L (en) |
| NZ (1) | NZ525821A (en) |
| PE (1) | PE20020792A1 (en) |
| PL (1) | PL361934A1 (en) |
| SK (1) | SK8242003A3 (en) |
| TW (1) | TW591023B (en) |
| WO (1) | WO2002053561A1 (en) |
| ZA (1) | ZA200304311B (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5284957A (en) * | 1992-09-03 | 1994-02-08 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
| EP1053234A1 (en) * | 1998-02-06 | 2000-11-22 | Smithkline Beecham Plc | Salts of paroxetine |
| GB9908175D0 (en) * | 1999-04-09 | 1999-06-02 | Lilly Co Eli | Method of treating neurological disorders |
| TR200200066T2 (en) * | 1999-07-06 | 2002-04-22 | Eli Lilly And Company | Selective iGluR5 receptor antagonists for the treatment of migraine |
-
2001
- 2001-12-20 PL PL01361934A patent/PL361934A1/en not_active Application Discontinuation
- 2001-12-20 MX MXPA03005981A patent/MXPA03005981A/en unknown
- 2001-12-20 CN CNA018217508A patent/CN1484642A/en active Pending
- 2001-12-20 BR BR0116672-7A patent/BR0116672A/en not_active IP Right Cessation
- 2001-12-20 WO PCT/US2001/044715 patent/WO2002053561A1/en not_active Application Discontinuation
- 2001-12-20 NZ NZ525821A patent/NZ525821A/en unknown
- 2001-12-20 IL IL15613801A patent/IL156138A0/en unknown
- 2001-12-20 HU HU0302528A patent/HUP0302528A2/en unknown
- 2001-12-20 CA CA002431545A patent/CA2431545A1/en not_active Abandoned
- 2001-12-20 EP EP01995980A patent/EP1351955A1/en not_active Withdrawn
- 2001-12-20 KR KR10-2003-7008977A patent/KR20030066797A/en not_active Application Discontinuation
- 2001-12-20 DZ DZ013460A patent/DZ3460A1/en active
- 2001-12-20 CZ CZ20031856A patent/CZ20031856A3/en unknown
- 2001-12-20 EA EA200300770A patent/EA200300770A1/en unknown
- 2001-12-20 JP JP2002554680A patent/JP2004520335A/en active Pending
- 2001-12-20 SK SK824-2003A patent/SK8242003A3/en unknown
-
2002
- 2002-01-04 AR ARP020100030A patent/AR035679A1/en not_active Application Discontinuation
- 2002-01-04 PE PE2002000003A patent/PE20020792A1/en not_active Application Discontinuation
- 2002-01-04 TW TW091100071A patent/TW591023B/en not_active IP Right Cessation
-
2003
- 2003-06-02 ZA ZA200304311A patent/ZA200304311B/en unknown
- 2003-06-27 NO NO20032973A patent/NO20032973L/en not_active Application Discontinuation
- 2003-07-03 HR HR20030544A patent/HRP20030544A2/en not_active Application Discontinuation
- 2003-07-03 EC EC2003004682A patent/ECSP034682A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004520335A (en) | 2004-07-08 |
| IL156138A0 (en) | 2003-12-23 |
| KR20030066797A (en) | 2003-08-09 |
| TW591023B (en) | 2004-06-11 |
| CA2431545A1 (en) | 2002-07-11 |
| MXPA03005981A (en) | 2003-09-10 |
| EA200300770A1 (en) | 2003-10-30 |
| HRP20030544A2 (en) | 2004-08-31 |
| PE20020792A1 (en) | 2002-09-06 |
| DZ3460A1 (en) | 2002-07-11 |
| PL361934A1 (en) | 2004-10-18 |
| EP1351955A1 (en) | 2003-10-15 |
| SK8242003A3 (en) | 2004-01-08 |
| NO20032973D0 (en) | 2003-06-27 |
| NZ525821A (en) | 2004-07-30 |
| CN1484642A (en) | 2004-03-24 |
| CZ20031856A3 (en) | 2003-09-17 |
| ECSP034682A (en) | 2003-08-29 |
| NO20032973L (en) | 2003-06-27 |
| HUP0302528A2 (en) | 2003-11-28 |
| WO2002053561A1 (en) | 2002-07-11 |
| AR035679A1 (en) | 2004-06-23 |
| ZA200304311B (en) | 2004-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0518459A2 (en) | compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, use of a compound, and process for preparing the compound or a pharmaceutically acceptable salt thereof | |
| BR0307351A (en) | Compound, pharmaceutical composition, method for treating a p38 kinase activity-mediated or cytokine-mediated condition or condition produced by p38 kinase activity, use of a compound, and process for preparing a compound | |
| BRPI0410477A (en) | compound or a pharmaceutically acceptable salt thereof, method for the prophylaxis or treatment of a chiral condition in a mammal, pharmaceutical formulation, combination, use of a compound, and process for preparing a compound | |
| BR0207526A (en) | Compound, pharmaceutical composition, and methods for treating pain, migraine, depression, anxiety, schizophrenia, parkinson's disease, or stroke | |
| BR0108610A (en) | Azapolycyclic compounds condensed with aryl | |
| BG66094B1 (en) | Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents | |
| BRPI0517423A (en) | compound, pharmaceutical composition, method for treating or preventing neurological and psychiatric disorders associated with glutamate dysfunction in an animal, and, use in a compound | |
| BRPI0507786A (en) | compound and pharmaceutically acceptable salts thereof, pharmaceutical formulation, use of a compound, method of treating a disease, and process for preparing compounds | |
| BR0213242A (en) | Compound or a salt or solvate thereof, compound and physiologically acceptable acid addition salts thereof, pharmaceutical composition, method of treating one or more disorders, use of a compound, and process of preparing a compound | |
| BRPI0412347A (en) | 2-Aminophenyl-4-phenylpyridines as kinase inhibitors | |
| BR0210122A (en) | Compound or a pharmaceutically acceptable salt thereof, method for treating or preventing a disease, use of the compound or salt thereof, and method for preparing the same | |
| BR0317435A (en) | Pyrimidine Derivatives for the Treatment of Abnormal Cell Growth | |
| BR0205829A (en) | Novel amines as histamine-3 receptor ligands and their therapeutic applications | |
| BR0212042A (en) | Compound, pharmaceutical composition, method of treating or preventing disease, and use of a compound | |
| BR0201437A (en) | Process for preparing 4-substituted 9-deoxo-9a-aza-9a-homoerythromycin derivatives | |
| BRPI0215312B8 (en) | compound, use of a compound, pharmaceutical composition, and process for preparing a compound | |
| NO20050088L (en) | Cationically substituted diphenylazofidinones, processes for their preparation, medicaments containing said compounds, and use thereof | |
| DK1689721T3 (en) | Aminopyrazole derivatives as GSK-3 inhibitors | |
| BR9909844A (en) | Process for synthesizing a compound, e, compound. | |
| BRPI0408353A (en) | compound, pharmaceutical composition, methods for the treatment of susceptible neoplasms and for the treatment of viral infections, and, use of a compound | |
| BR0211118A (en) | Compound, methods for treating or preventing disease and for making a compound, intermediate, and use of a compound or salt | |
| BRPI0410316A (en) | compound, pharmaceutical composition, use of the compounds, and method of treating vr1-mediated disorders and for the treatment of pain disorders | |
| BRPI0411891A (en) | pyrazol [3,4-b] pyridin-6-ones as gsk-3 inhibitors | |
| BR0113590A (en) | 7-oxopyridopyrimidines | |
| BR0313727A (en) | Isoquinoline derivatives as matrix metalloproteinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 1964 DE 26/08/2008 E CONSIDERANDO A AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS. |